Responses
ORIGINAL ARTICLE
Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.